Intellia Therapeutics has had a bruising long run for shareholders, with the stock still down sharply over the past five years even after a positive year to date. That leaves a clear question about how its current US$11.35 share price lines up with the sales it is generating today. With fresh milestones in gene editing and late stage programs back in focus, investors are increasingly asking whether the revenue base behind Intellia now justifies where the stock trades. Over the last 5 years,...
Intellia Therapeutics approaches a FDA decision in March 2027 for lonvo-z. Discover more on the NTLA's program and why a positive outcome is anticipated.
Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include patient perspective about life after lonvo-z treatmentIntellia to host investor webcast on Thursday, November 12 at 10 a.m. ET CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolution
Cathie Wood’s Ark Invest stepped up its semiconductor, biotechnology and technology exposure during the week ended October 2,
Intellia Therapeutics (NASDAQ:NTLA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call
This biotech has grabbed plenty of headlines recently.
Intellia update: Claude AI flags a gene-editing setup but can’t replicate it. Lonvo-z targets a 2027 launch; Nex-z enrollment rebounds. Click for more on NTLA stock.
Gene editing stocks fall as Anthropic’s (ANTHRO) AI model Claude discovers a new enzyme system similar to the gene-editing tool CRISPR. Read more here.
Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
Intellia Therapeutics (NTLA) has spent years being valued as a gene-editing science project.
I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Intellia Therapeutics (NTLA).
Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.
Intellia Therapeutics (NTLA) stock gains on FDA priority review for lonvo-z, a gene editing therapy for a rare condition called hereditary angioedema. Read more here.
Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.
Intellia Therapeutics (NTLA) said Tuesday that the US Food and Drug Administration has accepted the
This is the newest page. Registered accounts read further back.